There is no verified public evidence of a direct business partnership, family relationship, shared board position, or employer connection between John Grayken and Bruce Broussard. Grayken is best known as the founder and chairman of Lone Star Funds, while Broussard is the former Humana chief executive who became interim CEO of HP Inc. in February 2026.
Their names can appear together because both are prominent executives with long careers involving large corporations, investments, healthcare related businesses, and Texas based professional networks. Those broad similarities should not be mistaken for evidence that they have personally worked together.
John Grayken and Bruce Broussard at a Glance
| Detail | John Grayken | Bruce Broussard |
|---|---|---|
| Primary field | Private equity and investment management | Corporate leadership, healthcare and technology |
| Best known for | Founding Lone Star Funds | Former CEO of Humana |
| Current major role | Founder and Chairman of Lone Star Funds | Interim CEO of HP Inc. |
| Major organizations | Lone Star Funds, Hudson | HP, Humana, US Oncology, McKesson |
| Current board activity | Lone Star leadership | HP, Marsh McLennan, Takeda |
| Verified direct relationship | No public evidence found | No public evidence found |
As of September 2026, Lone Star identifies Grayken as its founder and chairman, while Donald Quintin serves as the firm’s CEO and Global President. HP continues to identify Broussard as its interim CEO and a director.
Who Is John Grayken?
John P. Grayken is the founder and chairman of Lone Star Funds, an investment organization that focuses on private equity, credit and real estate opportunities.
Lone Star says Grayken has been investing through the organization for more than 30 years. Since the establishment of its first fund in 1995, the firm has organized funds representing approximately $96 billion in aggregate capital commitments.
Grayken also founded Hudson, an asset management business that provides advisory, administrative and operational support to Lone Star’s investment activities. According to Lone Star, Hudson has advised its funds on roughly 1.1 million assets representing an aggregate purchase price of approximately $284 billion.
Grayken’s Role at Lone Star Today
Grayken remains chairman, but he is no longer presented as the person responsible for Lone Star’s day to day management.
In 2024, Donald J. Quintin became Lone Star’s Chief Executive Officer and Global President. Lone Star says Quintin leads its overall management and global strategy, while Grayken remains founder and chairman.
That distinction matters when looking for possible connections involving Grayken. A modern Lone Star transaction does not automatically mean Grayken personally negotiated it or dealt directly with executives connected to the other company.
What Lone Star Funds Does
Lone Star describes itself as a global value investor working across three principal areas:
- private equity
- credit
- real estate
Its investment strategy often involves complicated businesses, assets or financial situations where the firm believes restructuring, operational improvements, financing or other changes can create value. The organization has offices in locations including Dallas, New York, London, Tokyo and Singapore.
This makes Grayken’s professional sphere primarily one of capital allocation, acquisitions, distressed opportunities and private market investing.
Who Is Bruce Broussard?
Bruce D. Broussard is an American corporate executive whose career has been concentrated mainly in healthcare, insurance and large company management.
He became particularly well known during his lengthy tenure at Humana, one of the largest health insurers and healthcare services companies in the United States.
Before Humana, Broussard spent approximately 11 years with US Oncology, holding positions that included Chief Financial Officer, President, Chief Executive Officer and Chairman. When US Oncology was sold to McKesson, he became President of McKesson’s Specialty Pharmacy Division.
Broussard’s Humana Career
Broussard joined Humana as president in 2011 and became CEO in 2013. He remained at the head of the company for more than a decade.
Humana completed a planned leadership transition on July 1, 2024, when Jim Rechtin became President and CEO and Broussard stepped down from both the chief executive position and Humana’s board. Humana said Broussard would continue as a strategic adviser into 2026.
His Humana tenure made him one of the more recognizable executives in the US managed healthcare industry.
Bruce Broussard Became Interim CEO of HP in 2026
Broussard’s career took a significant turn on February 3, 2026.
HP announced that Enrique Lores had stepped down as President and CEO and that Broussard, already an HP director since 2021, had been appointed Interim Chief Executive Officer effective immediately. HP also established a CEO search committee to identify a permanent successor.
HP continues to identify Broussard as its interim CEO. His move to HP broadened his executive career beyond healthcare into a major global technology company.
An SEC filing concerning the appointment states that Broussard’s interim CEO compensation includes $362,500 in monthly cash compensation plus a one time restricted stock unit award with a grant date value of $7 million, subject to the applicable plan and award terms. These numbers describe compensation arrangements, not Broussard’s personal net worth.
Is There a Direct Connection Between John Grayken and Bruce Broussard?
Based on currently available corporate records and authoritative public information, no direct connection between John Grayken and Bruce Broussard has been established.
Their documented careers do not show them serving together at Lone Star Funds, Hudson, Humana, US Oncology, McKesson or HP. Their currently disclosed board positions also do not establish a shared directorship.
Grayken’s official Lone Star biography describes his career through Lone Star and Hudson. Broussard’s current corporate biographies trace his career through organizations including US Oncology, McKesson, Humana and HP. Neither biography identifies the other man as a colleague, business partner or associate.
This does not prove the two individuals have never met. High level executives and investors often attend the same conferences, work with overlapping financial institutions or move within similar professional networks. It simply means a meaningful personal or commercial relationship cannot be responsibly claimed from the public evidence currently available.
Also Read: Toshihiro Suzuki and Bruce Broussard
Could Lone Star’s Healthcare Investments Explain the Search?
There is one area where the professional worlds surrounding Grayken and Broussard have become somewhat closer: healthcare and pharmaceutical related investment.
In March 2026, Lonza announced an agreement to sell its Capsules & Health Ingredients business to Lone Star Funds for an enterprise value of CHF 2.3 billion, reported by Lonza as approximately $3 billion at closing. Lonza agreed to retain a 40 percent stake.
The business includes pharmaceutical and nutraceutical capsule manufacturing, dosage form solutions and health ingredients. That places Lone Star in an industry related to Broussard’s long healthcare career.
However, the transaction should not be described as a Grayken Broussard deal.
Lonza’s announcement names Lone Star as the buyer but provides no indication that Broussard participated in the transaction. Broussard’s disclosed positions in 2026 include HP and external directorships elsewhere, not employment by Lone Star or Lonza’s Capsules & Health Ingredients business.
The healthcare overlap is therefore contextual rather than evidence of a personal connection.
Bruce Broussard’s Current Board Roles
Broussard has continued to build a broad corporate governance portfolio since leaving Humana.
Marsh McLennan
Marsh McLennan appointed Broussard to its board on July 9, 2025. The company highlighted his experience in healthcare, insurance and executive management.
Takeda Pharmaceutical
In 2026, Broussard was nominated to the board of Japanese pharmaceutical company Takeda. Takeda’s current leadership information identifies him as an External Director and member of its Audit and Supervisory Committee.
His Takeda biography also confirms his career progression through Harbor Dental, US Oncology, McKesson, Humana, Marsh McLennan and HP.
Other Organizations
HP’s current biography for Broussard also identifies him as a board member of the Cleveland Clinic and a trustee of the Trust for the National Mall, while noting his involvement with the Business Council.
None of those disclosed roles creates a documented organizational link to Grayken.
How Their Careers Differ
The clearest way to understand John Grayken and Bruce Broussard is to look at the functions they have performed.
Grayken Is Primarily an Investor
Grayken built his reputation by identifying, financing and managing investments through private funds.
The Lone Star model involves purchasing companies, financial assets, debt and real estate, frequently in situations involving complexity or restructuring. Grayken’s influence has therefore largely operated through ownership and investment capital.
Broussard Is Primarily an Operating Executive
Broussard’s career has focused much more heavily on managing businesses directly.
At US Oncology, Humana and now HP, his responsibilities have involved corporate operations, financial management, strategy and organizational leadership. His subsequent board positions draw heavily on that operating experience.
Put simply, Grayken’s career has centered on investing in businesses and assets, while Broussard’s has largely centered on running and governing businesses.
What the Two Executives Do Have in Common
Although there is no verified direct relationship, several broad similarities help explain why their names may appear within the same business research.
Both have spent decades dealing with large organizations and complex financial decisions. Each has significant experience with acquisitions and corporate strategy, although from different sides of transactions.
There is also a geographic overlap involving Texas. Lone Star maintains a major Dallas presence, while Broussard earned his undergraduate degree in accounting and finance from Texas A&M University and an MBA in finance from the University of Houston.
That geographic connection is interesting background, but it is not evidence of a business relationship.
Their professional networks may also intersect indirectly through banks, institutional investors, advisers, insurers, healthcare businesses or corporate boards. Large company ecosystems routinely create such indirect connections without establishing a meaningful relationship between two individual executives.
Current Status of John Grayken and Bruce Broussard
As of September 2026, their current positions remain clearly separate.
John Grayken remains founder and chairman of Lone Star Funds. The firm marked its 30th anniversary in 2025 and continues to pursue transactions globally, while Donald Quintin serves as CEO and Global President. Lone Star’s September 2026 news page shows continuing activity across technology related real estate, industrial businesses and property investments.
Bruce Broussard is serving as interim CEO of HP Inc. after taking the position in February 2026. He also holds board positions with Marsh McLennan and Takeda Pharmaceutical.
Nothing in those current positions establishes a shared venture between the two.
Why It Is Important Not to Invent a Relationship
Searches combining two well known businesspeople sometimes lead to pages that imply a partnership, investment or personal relationship without providing primary evidence.
For John Grayken and Bruce Broussard, the verifiable record supports separate professional biographies rather than a documented partnership.
A credible connection would normally require evidence such as a corporate filing, board appointment, acquisition announcement, investment disclosure, joint venture record, company biography, direct interview or reliable news report naming both individuals in the same transaction or organization.
No such evidence has been identified in the authoritative sources reviewed for this article.
Frequently Asked Questions
Are John Grayken and Bruce Broussard business partners?
There is no reliable public evidence showing that John Grayken and Bruce Broussard are business partners. Grayken’s documented career centers on Lone Star Funds and Hudson, while Broussard’s career includes US Oncology, McKesson, Humana and HP.
Did Bruce Broussard work for Lone Star Funds?
No credible corporate record reviewed for this article shows Broussard working for Lone Star Funds. His official biographies instead document executive positions at US Oncology, McKesson, Humana and HP, together with several board appointments.
Did John Grayken work at Humana?
There is no evidence in Lone Star’s official leadership history or Humana’s documented Broussard succession material showing Grayken as a Humana executive. Grayken is identified by Lone Star as its founder and chairman.
What company did John Grayken found?
Grayken founded Lone Star Funds and also founded Hudson, the asset management organization that supports Lone Star’s investment activities. Lone Star says its funds now represent approximately $96 billion in aggregate capital commitments.
What does Bruce Broussard do now?
As of September 2026, Broussard is the interim CEO of HP Inc. HP appointed him to the position effective February 3, 2026. He also serves as a director at organizations including Marsh McLennan and Takeda Pharmaceutical.
Is there a healthcare connection between Grayken and Broussard?
Only an indirect industry overlap can currently be documented. Broussard has spent much of his career in healthcare, while Lone Star agreed in 2026 to acquire Lonza’s Capsules & Health Ingredients business. Public documentation of that transaction does not identify Broussard as a participant.
Also Read: Shiv Nadar and Bruce Broussard
